Singapore markets open in 8 hours 47 minutes
Straits Times Index
3,439.88 +24.37 (+0.71%) S&P 500
5,537.02 +28.01 (+0.51%) Dow
39,308.00 -23.90 (-0.06%) Nasdaq
18,188.30 +159.54 (+0.88%) Bitcoin USD
57,890.73 -2,319.77 (-3.85%) CMC Crypto 200
1,212.98 -48.20 (-3.82%)
Vertex Pharmaceuticals Inc (VX1.SG)
Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
As of 04:19PM CEST. Market open.
| Previous close | 435.85 |
| Open | 434.10 |
| Bid | 435.40 x 50000 |
| Ask | 437.20 x 100000 |
| Day's range | 434.10 - 437.30 |
| 52-week range | 307.15 - 450.15 |
| Volume | |
| Avg. volume | 27 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Vertex (VRTX) NDA for Vanza Triple Therapy Accepted by FDA
The FDA accepts Vertex's (VRTX) new drug application for vanza triple therapy for people living with cystic fibrosis aged six years and above. A decision is due on Jan 2, 2025.
- GuruFocus.com
Insider Sale at Vertex Pharmaceuticals Inc (VRTX): EVP and CMO Carmen Bozic Sells 2,280 Shares
The transaction was executed at a price of $471.72 per share, as detailed in the SEC Filing. Following this sale, the insider now owns 30,099 shares of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc (NASDAQ:VRTX) is a biotechnology firm focused on developing and commercializing therapies for the treatment of cystic fibrosis and other severe diseases.
- Zacks
Vertex (VRTX) Rises 16.5% YTD: Time to Bet On the Stock?
While CF remains the main area of focus, Vertex (VRTX) has seen rapid success in its non-CF pipeline candidates' development in the past year.
© 2024 Yahoo. All rights reserved.